Literature DB >> 9271215

Comparison of PMM1 with the phosphomannomutases expressed in rat liver and in human cells.

M Pirard1, J F Collet, G Matthijs, E Van Schaftingen.   

Abstract

Carbohydrate-deficient glycoprotein syndrome type I (CDGI) is most often due to phosphomannomutase deficiency; paradoxically, the human phosphomannomutase gene PMM1 is located on chromosome 22, whereas the CDGI locus is on chromosome 16. We show that phosphomannomutases present in rat or human liver share with homogeneous recombinant PMM1 several kinetic properties and the ability to form an alkali- and NH2OH-sensitive phosphoenzyme with a subunit mass of approximately 30,000 Mr. However, they have a higher affinity for the activator mannose-1,6-bisphosphate than PMM1 and are not recognized by anti-PMM1 antibodies, indicating that they represent a related but different isozyme. Phosphomannomutases belong to a novel mutase family in which the active residue is a phosphoaspartyl or a phosphoglutamyl.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271215     DOI: 10.1016/s0014-5793(97)00704-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  From structure to function: YrbI from Haemophilus influenzae (HI1679) is a phosphatase.

Authors:  James F Parsons; Kap Lim; Aleksandra Tempczyk; Wojiech Krajewski; Edward Eisenstein; Osnat Herzberg
Journal:  Proteins       Date:  2002-03-01

2.  BeF(3)(-) acts as a phosphate analog in proteins phosphorylated on aspartate: structure of a BeF(3)(-) complex with phosphoserine phosphatase.

Authors:  H Cho; W Wang; R Kim; H Yokota; S Damo; S H Kim; D Wemmer; S Kustu; D Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes.

Authors:  M Pirard; Y Achouri; J F Collet; E Schollen; G Matthijs; E Van Schaftingen
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

4.  Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A.

Authors:  G Matthijs; E Schollen; E Van Schaftingen; J J Cassiman; J Jaeken
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development.

Authors:  K Cromphout; W Vleugels; L Heykants; E Schollen; L Keldermans; R Sciot; R D'Hooge; P P De Deyn; K von Figura; D Hartmann; C Körner; G Matthijs
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

6.  Evolutionary history and functional diversification of phosphomannomutase genes.

Authors:  Rita Quental; Ana Moleirinho; Luísa Azevedo; António Amorim
Journal:  J Mol Evol       Date:  2010-07-27       Impact factor: 2.395

7.  Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-bisphosphatase.

Authors:  Maria Veiga-da-Cunha; Wendy Vleugels; Pushpa Maliekal; Gert Matthijs; Emile Van Schaftingen
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

8.  Phosphoglucomutase is absent in Trypanosoma brucei and redundantly substituted by phosphomannomutase and phospho-N-acetylglucosamine mutase.

Authors:  Giulia Bandini; Karina Mariño; M Lucia Sampaio Güther; Amy K Wernimont; Sabine Kuettel; Wei Qiu; Shamshad Afzal; Anna Kelner; Raymond Hui; Michael A J Ferguson
Journal:  Mol Microbiol       Date:  2012-07-12       Impact factor: 3.501

9.  Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.

Authors:  Giuseppina Andreotti; Maria Chiara Monti; Valentina Citro; Maria Vittoria Cubellis
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

10.  Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation.

Authors:  Giuseppina Andreotti; Emilia Pedone; Assunta Giordano; Maria Vittoria Cubellis
Journal:  Mol Genet Genomic Med       Date:  2013-03-27       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.